- Mar 23, 2007
For the first time, Europe's largest drugs company, GSK, is starting the registration process for a vaccine from which it never expects to make money.
Globorix will only be used in Africa to prevent meningitis at prices that may never cover its research costs.
Read more here.
Good to see GSK is trying to do some good and that it sees it as a strategic business practice and not just good PR.